Skip to content

Efficacy and safety of nano-curcumin on the clinical condition of patients with hemorrhagic stroke

Efficacy and Safety of nano-curcumin on the clinical condition of patients with hemorrhagic stroke: A randomized, assessor-blind, parallel-group pilot study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140221016666N4
Enrollment
40
Registered
2020-11-30
Start date
2021-01-04
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracerebral hemorrhage. Nontraumatic intracerebral hemorrhage

Interventions

Intervention 1: Intervention group: Nano-curcumin medication with dosage of 80 mg for 12 weeks. Intervention 2: Control group: Patients with cerebral hemorrhage without medication.

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 18-80 years, Diagnosis of ICH by brain CT scan, NIHSS> 4 and MRS <2 presymptomatic, bleeding in the putamen area, Glasgow criterion (GCS greater than 8) informed consent of the patient or first-degree relatives.

Exclusion criteria

Exclusion criteria: Allergy to turmeric, pregnancy, liver disease with liver enzyme more than three times of normal range kidney disease or creatine more than 2, candidate for surgery and hematoma evacuation, secondary ICH for anticoagulant use and tumor and aneurysm and AVM, infratentorial hemorrhage, platelet count / 75,000 mm3 <, INR <1.4, fever at initial visit, other inflammatory diseases including pneumonia, hematology, rheumatology, urinary tract infection on admission. Immune suppressant drugs,] absorption syndromes, history of diabetes, smoking, alcohol and drug use

Design outcomes

Primary

MeasureTime frame
Improvement of the patient's disability and dysfunction to achieve MRS is below 3. Timepoint: At the time of admission, 24, 48 and 72 hours, 1 week (or last day of hospitalization), 4 weeks and 12 weeks. Method of measurement: MRS questionnaire.

Secondary

MeasureTime frame
Reduce NIHSS to less than the initial 50% and reduce hematoma volume and increase Glasgow score. Timepoint: At the time of admission, 24, 48 and 72 hours, 1 week (or last day of hospitalization), 4 weeks and 12 weeks. Method of measurement: Hematoma size is measured using the formula ABC / 2 (A: The largest diameter in the largest bleeding slice, B the diameter perpendicular to A and C, the approximate number of 10 mm slices in which bleeding occurs). NIHSS Questionnaire and Glasgow scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarges Karimi

Mazandaran University of Medical Sciences

drkarimi_236@yahoo.com+98 11 3311 6275

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026